High growth rate of the gout therapeutics market is attributed because of following factors
- Increase in drug pipeline
- Easy availability,
- Rise in the demand for biologics for treatment of gout across the globe.
Gout is a type of inflammatory arthritis caused by small crystals of a chemical called uric acid that form in the joints. If uric acid levels in the blood remain elevated, thin rod-like crystals can form and deposit in the joints, which can lead to severe pain, tenderness, stiffness, swelling, and joint damage.
Gout has both active and inactive periods. Active periods of gout are known as ‘attacks’ and can vary in severity and length. Diagnosis of gout is confirmed by synovial fluid analysis. Incidence of gout has been rising consistently over the last few years.
- According to Nationwide Emergency Department Sample (NEDS), total number of ED visits per year among patients with a primary diagnosis of acute gout increased 26.8% between 2006 and 2014; from 168,580 to 213,780.
Traditional therapies are witnessing a shift toward biologics. Rise in demand for effective treatment and new therapeutics launches are projected to propel the global gout therapeutics market during the forecast period. Efforts are being taken in various countries to spread awareness about chronic diseases and role of biologics in treating gout among the general population.
Request Sample Of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=66875
No comments:
Post a Comment